 |
Dehydroepiandrosterone |
|---|---|
| Trade Name | |
| Orphan Indication | Systemic lupus erythematosus (SLE) and the reduction in the use of steroids in steroid-dependent SLE patients |
| USA Market Approval | USA |
| USA Designation Date | 1994-07-13 00:00:00 |
| Sponsor | GlaxoSmithKline;P. O. Box 13398, Five Moore Drive;Research Triangle Park, North Carolina, 27709 |
